Wednesday, July 8, 2026

Drug profile · INN

ethacrynate sodium

ethacrynate sodium (ETHACRYNATE SODIUM) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ethacrynate sodium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

ethacrynate sodium (ETHACRYNATE SODIUM) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN ethacrynate sodium
Brand ETHACRYNATE SODIUM
Mechanism Sodium-(potassium)-chloride cotransporter 2 inhibitor
Target Solute carrier family 12 member 1
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Sodium-(potassium)-chloride cotransporter 2 inhibitor

Primary target: Solute carrier family 12 member 1

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor
  2. ethacrynic acid Sodium-(potassium)-chloride cotransporter 2 inhibitor
  3. furosemide Cardiovascular system (C03)
  4. torsemide Sodium-(potassium)-chloride cotransporter 2 inhibitor

Frequently asked questions

What is ethacrynate sodium?

ethacrynate sodium (ETHACRYNATE SODIUM) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for ethacrynate sodium?

ETHACRYNATE SODIUM is a marketed brand name for ethacrynate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ethacrynate sodium?

ethacrynate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.